2-吗啉-4-基吡啶并[1,2-a]嘧啶-4-酮 | 17326-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: 2-吗啉-4-基吡啶并[1,2-a]嘧啶-4-酮
• 英文名称: 2-morfolino-4H-pirido<1,2-a>pirimidin-4-one
• 英文别名: 2-morpholinopyrido[1,2-a]pyrimidin-4(4H)-one；2-Morpholino-4-oxo-4H-pyrido<1,2-a>pyrimidin；2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one；2-Morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one
• CAS: 17326-31-7
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: VDMRPNTZWKDYBB-UHFFFAOYSA-N

物化性质

• 熔点：
  188-189 °C(Solv: isopropanol (67-63-0))
• 沸点：
  395.7±52.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氯-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-甲醛 在 air 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 10.0h， 生成 2-吗啉-4-基吡啶并[1,2-a]嘧啶-4-酮
  参考文献：
  名称：

  功能化偶氮甲碱叶立德的生成及其在立体选择性杂环合成中的应用：C-未取代的腈叶立德环加成反应的等效过程

  摘要：

  摘要 通过NH-偶氮甲碱叶立德的环加成和随后的环加合物在酸性条件下的裂变反应，实现了相当于C-未取代(CH)腈叶立德环加成反应的合成过程。在 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde 系统中由热 1,2-prototropy 生成的 NH-azomethine 叶立德与马来酰亚胺在极其温和的条件下进行环加成反应提供脯氨酸衍生物。在 85 °C 下在 AcOH 中加热它们的加合物会导致脯氨酸和杂环部分之间的 C-C 键断裂，得到母体杂环系统和脱氢脯氨酸衍生物，它被认为是 C-未取代 (CH) 腈叶立德的环加合物。这种环加成裂变反应序列可应用于一锅三组分反应。

  DOI：

  10.1016/j.tet.2006.12.004

文献信息

• Therapeutic morpholino-substituted compounds
  申请人：Robertson D. Alan

  公开号：US20050085471A1

  公开（公告）日：2005-04-21

  Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders, neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

  Morpholino取代的吡啶并[3,4-d]吡嗪、喹诺酮和苯并吡喃衍生物抑制磷脂酰肌醇（PI）3-激酶，该酶调节血小板粘附过程。因此，所述化合物具有抗血栓活性，以及其他药物特性。所声称的化合物由公式（I）、（II）和（III）表示。PI 3-激酶产生3-磷酸化的PI第二信使，在血流条件下刺激血小板粘附。由于血小板粘附是形成血栓的必要步骤，这些化合物在此类条件下抑制PI 3-激酶会抑制或预防血栓形成。这些化合物可用于治疗PI 3-激酶依赖性疾病，包括心血管疾病，如冠状动脉闭塞、中风、急性冠状动脉综合征、急性心肌梗死、血管再狭窄、动脉粥样硬化和不稳定性心绞痛；呼吸系统疾病，如哮喘、慢性阻塞性肺疾病（COPD）和支气管炎；炎症性疾病、肿瘤包括胶质瘤、前列腺癌、小细胞肺癌和乳腺癌，以及与白细胞功能紊乱相关的疾病，如自身免疫和炎症性疾病。
• Therapeutic Morpholino-Substituted Compounds
  申请人：Robertson Alan D.

  公开号：US20080206312A1

  公开（公告）日：2008-08-28

  Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

  Morpholino取代的吡啶并[3,4-d]吡嗪、喹诺酮和苯并吡喃衍生物抑制磷脂酰肌醇（PI）3-激酶，一种调节血小板粘附过程的酶。因此，所述化合物具有抗血栓活性以及其他药物性质。所要求的化合物由公式（I）、（II）和（III）表示。PI 3-激酶产生3-磷酸化PI第二信使，在血流条件下刺激血小板粘附。由于血小板粘附是形成血栓的必要步骤，这些化合物在这种条件下抑制PI 3-激酶会抑制或预防血栓形成。这些化合物可用于治疗PI 3-激酶依赖性疾病，包括心血管疾病，如冠状动脉闭塞、中风、急性冠状动脉综合症、急性心肌梗死、血管再狭窄、动脉粥样硬化和不稳定性心绞痛；呼吸系统疾病，如哮喘、慢性阻塞性肺疾病（COPD）和支气管炎；炎症性疾病；肿瘤，包括胶质瘤、前列腺癌、小细胞肺癌和乳腺癌等癌症；以及与白细胞功能紊乱有关的疾病，如自身免疫性和炎症性疾病。
• Roma, G.; Ermili, A.; Braccio, M. Di, Farmaco, Edizione Scientifica, 1982, vol. 37, # 11, p. 747 - 758
  作者：Roma, G.、Ermili, A.、Braccio, M. Di、Mazzei, M.

  DOI：——

  日期：——
• Ingalls,E.A.; Popp,F.D., Journal of Heterocyclic Chemistry, 1967, vol. 4, p. 523 - 526
  作者：Ingalls,E.A.、Popp,F.D.

  DOI：——

  日期：——
• ROMA, G.;ERMILI, A.;DI, BRACCIO, M.;MAZZEI, M., FARMACO. ED. SCI., 1982, 37, N 11, 747-758
  作者：ROMA, G.、ERMILI, A.、DI, BRACCIO, M.、MAZZEI, M.

  DOI：——

  日期：——